{"entity":{"id":"joseph-gligorov","kind":"person","name":"Joseph Gligorov","aka":[],"tldr":"Medical oncologist at Hôpital Tenon who is executive director of the Institut Universitaire de Cancérologie AP-HP Sorbonne Université, the OECI-accredited university cancer institute in Paris.","summary":"Joseph Gligorov is Directeur Exécutif of the Institut Universitaire de Cancérologie (IUC) AP-HP Sorbonne Université, which coordinates cancer care, teaching and research across the AP-HP Sorbonne Université hospital group and the university's health faculty. He is professor of medical oncology at Sorbonne Université, practises in the medical oncology department of Hôpital Tenon in Paris and belongs to the Inserm U938 team on cancer biology and treatment; his research concerns breast cancer and predictive factors of response to anticancer treatment, he directs the Nice-St Paul de Vence breast cancer guidelines conference and he co-founded and chairs the Mediterranean oncology association AROME. In a 2023 interview with the Sorbonne Université Faculté de Santé, as director of the IUC, he described the institute's creation by Dean Serge Uzan and its accreditation as an OECI 'Comprehensive Cancer Center', and AP-HP reported in February 2026 on the institute's annual scientific day.","asOf":"2026-09-10","links":[{"label":"Source: Alliance Sorbonne Université Global Health Institute profile naming him Directeur Exécutif of the IUC","url":"https://asu-ghi.sorbonne-universite.fr/lasu-ghi/membres/joseph-gligorov"},{"label":"Source: Sorbonne Université Faculté de Santé interview with the IUC director on OECI accreditation (2023)","url":"https://sante.sorbonne-universite.fr/actualites/linstitut-universitaire-de-cancerologie-iuc-decroche-laccreditation-comprehensive-cancer"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Directeur Exécutif (Executive Director), Institut Universitaire de Cancérologie AP-HP Sorbonne Université","institutionId":"iuc-aphp-sorbonne","specialisms":["Medical oncology","Breast cancer","Predictive factors of treatment response"],"profiles":[{"label":"ASU-GHI member profile (Sorbonne Université)","url":"https://asu-ghi.sorbonne-universite.fr/lasu-ghi/membres/joseph-gligorov"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gligorov+J%5BAuthor%5D"}],"papers":[{"title":"Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer","journal":"JAMA Oncology","year":2021,"doi":"10.1001/jamaoncol.2020.5660"},{"title":"COVID-19 et personnes suivies pour un cancer du sein : recommandations françaises pour la pratique clinique de Nice-St Paul de Vence, en collaboration avec le Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), la Société d’Imagerie de la Femme (SIFEM), la Société Française de Chirurgie Oncologique (SFCO), la Société Française de Sénologie et Pathologie Mammaire (SFSPM) et le French Breast Cancer Intergroup-UNICANCER (UCBG)","journal":"Bulletin du Cancer","year":2020,"doi":"10.1016/j.bulcan.2020.03.008"},{"title":"Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study","journal":"European Journal of Cancer","year":2017,"doi":"10.1016/j.ejca.2017.05.009"}],"orcid":"0000-0002-9900-6386"},"route":"/people/joseph-gligorov/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"institution":[{"id":"iuc-aphp-sorbonne","kind":"institution","name":"Institut Universitaire de Cancérologie AP-HP Sorbonne Université","route":"/institutions/iuc-aphp-sorbonne/"},{"id":"oeci","kind":"institution","name":"Organisation of European Cancer Institutes","route":"/institutions/oeci/"}]}}